Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AAIPharma/CML to Make Afimoxifene Gel for Atossa Genetics | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AAIPharma/CML to Make Afimoxifene Gel for Atossa Genetics

Initial production of the API will be completed by the end of 2015

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Atossa Genetics Inc. has signed manufacturing and quality agreements with AAIPharma Services Corp./Cambridge Major Laboratories Inc. for the manufacturing of a clinical supply for 4-Hydroxytamoxifen, the active pharmaceutical ingredient in Atossa’s leading drug candidate, Afimoxifene gel. In May 2015 Atossa acquired from Besins Healthcare the exclusive rights to Afimoxifene gel for the potential treatment of hyperplasia of the breast.

“Securing a manufacturing source for the API marks important progress of our clinical program,” said Steven Quay, chairman, chief executive officer and president, Atossa Genetics. “With the manufacturing and quality agreements in place, AAI/CML will now begin its work to manufacture a clinical supply of the API. We expect that the initial production of the API will be completed by the end of 2015 and once combined with the proprietary gel to form the clinical drug product we can then begin clinical studies in 2016.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics